An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NNC0174-0833 in Subjects With Normal Renal Function and Impaired Renal Function
Latest Information Update: 27 Jan 2021
Price :
$35 *
At a glance
- Drugs Cagrilintide (Primary)
- Indications Obesity; Overweight
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 22 Jan 2021 Status changed from active, no longer recruiting to completed.
- 14 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 22 Oct 2020 Planned primary completion date changed from 22 Sep 2020 to 26 Jan 2021.